LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro

SUMMARY Chronic rhinosinusitis with nasal polyps is a common disease with still unclear pathophysiologic mechanisms. The airway epithelial barrier has been shown to be involved in different chronic disorders, including rhinitis, nasal polyposis and asthma. High mobility group box 1 (HMGB1), a primarily nuclear protein, is involved in the induction of airway inflammation in patients with chronic rhinosinusitis, allergy, asthma and COPD. Pathogen-derived lipopolysaccharide is widely used as a trigger for inflammation. However, the molecular dialogue between LPS and HMGB1 in the delayed inflammatory processes remains to be explored, and the regulation of HMGB1 release through LPS from epithelial cells has not been extensively studied in patients with chronic rhinosinusitis and nasal polyps. The objective of the present study was to investigate the relocation of HMGB1 in LPS-induced human nasal epithelial cells in vitro. We obtained epithelial cells of nasal polyps from 10 patients requiring surgery for sinusitis at the ENT Department of the Chinese PLA General Hospital. The primary cultured human nasal epithelial (HNE) cells were stimulated with LPS. The expression and translocation of HMGB1 in intracellular and culture supernatants were determined using Western blot and immunofluorescence assay. HMGB1 protein was released in a time-dependent fashion in culture supernatants: in fact, expression of HMGB1 protein in HNE cells showed no significant changes at 0-24 h after exposure to 100 μg/ml LPS, but increased significantly at 48 and 72 hr. Immunofluorescence analysis revealed the transfer of HMGB1 from nuclei to cytoplasm in response to LPS exposure after 24 hr. These data reveal a hitherto unrecognized association between HMGB1 and LPS in human nasal epithelial cells. LPS can affect HMGB1 translocation and release, suggesting the involvement of HMGB1, through inflammatory mediators, in chronic rhinosinusitis with nasal polyps.

[1]  D. Passali,et al.  The role of High Mobility Group Box 1 chromosomal protein in the pathogenesis of chronic sinusitis and nasal polyposis , 2012, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[2]  Chuan-xin Wu,et al.  LPS induces HMGB1 relocation and release by activating the NF-κB-CBP signal transduction pathway in the murine macrophage-like cell line RAW264.7. , 2012, The Journal of surgical research.

[3]  Sang-Heon Cho,et al.  The role of high‐mobility group box‐1 (HMGB1) in the pathogenesis of asthma , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  S. Bonini,et al.  TLR4 and TLR9 Expression in Different Phenotypes of Rhinitis , 2012, International journal of otolaryngology.

[5]  D. Passali,et al.  High mobility group box 1 (HMGB 1): a new protein in the pathogenesis of ENT inflammatory and infectious diseases. , 2012, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[6]  J. Palmer,et al.  Inflammation-mediated upregulation of centrosomal protein 110, a negative modulator of ciliogenesis, in patients with chronic rhinosinusitis. , 2011, The Journal of allergy and clinical immunology.

[7]  C. Bachert,et al.  Pathogenesis of chronic rhinosinusitis: inflammation. , 2011, The Journal of allergy and clinical immunology.

[8]  P. Howarth,et al.  Defective epithelial barrier function in asthma. , 2011, The Journal of allergy and clinical immunology.

[9]  H. Tsutsumi,et al.  A nuclear factor-κB signaling pathway via protein kinase C δ regulates replication of respiratory syncytial virus in polarized normal human nasal epithelial cells , 2011, Molecular biology of the cell.

[10]  Zheng Liu,et al.  [The expression of IL-23 in nasal mucosa of allergic rhinitis patients and its significance]. , 2010, Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery.

[11]  A. Coyle,et al.  Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[12]  Xiang Chen,et al.  Expression of High Mobility Group Box Chromosomal Protein 1 and Its Modulating Effects on Downstream Cytokines in Systemic Lupus Erythematosus , 2010, The Journal of Rheumatology.

[13]  D. Tieu,et al.  Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis. , 2009, The Journal of allergy and clinical immunology.

[14]  A. Ribas,et al.  HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression , 2009, PLoS medicine.

[15]  J. Clancy,et al.  Potential role of high-mobility group box 1 in cystic fibrosis airway disease. , 2008, American journal of respiratory and critical care medicine.

[16]  P. Goldstraw,et al.  Differential Regulation of Cytokine Release and Leukocyte Migration by Lipopolysaccharide-Stimulated Primary Human Lung Alveolar Type II Epithelial Cells and Macrophages1 , 2007, The Journal of Immunology.

[17]  Yuh-Shyan Chen,et al.  Expression of Toll-like receptors in cultured nasal epithelial cells , 2007, Acta oto-laryngologica.

[18]  S. Durham,et al.  Functional endoscopic sinus surgery: 5 year follow up and results of a prospective, randomised, stratified, double-blind, placebo controlled study of postoperative fluticasone propionate aqueous nasal spray. , 2005, Rhinology.

[19]  U. Andersson,et al.  RAGE is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages , 2005, Scandinavian journal of immunology.

[20]  E. Abraham,et al.  Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein* , 2004, Journal of Biological Chemistry.

[21]  Tiziana Bonaldi,et al.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion , 2003, The EMBO journal.

[22]  G. Passali,et al.  Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis. , 2003, Archives of otolaryngology--head & neck surgery.

[23]  Michael Bustin,et al.  Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. , 2003, Blood.

[24]  Kim Bottomly,et al.  Lipopolysaccharide-enhanced, Toll-like Receptor 4–dependent T Helper Cell Type 2 Responses to Inhaled Antigen , 2002, The Journal of experimental medicine.

[25]  M. Bianchi,et al.  The nuclear protein HMGB1 is secreted by monocytes via a non‐classical, vesicle‐mediated secretory pathway , 2002, EMBO reports.

[26]  D. Beno,et al.  Splenectomy ablates endotoxin-induced IFNγ response in rats , 2002 .

[27]  O. Houcine,et al.  Effects of retinoic acid receptor-selective agonists on human nasal epithelial cell differentiation. , 2001, American journal of respiratory cell and molecular biology.

[28]  K. Tracey,et al.  HMGB1 as a late mediator of lethal systemic inflammation. , 2001, American journal of respiratory and critical care medicine.

[29]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[30]  Herman Goossens,et al.  European Position Paper on Rhinosinusitis and Nasal Polyps 2012. , 2012, Rhinology. Supplement.

[31]  Vineet Agrawal,et al.  Damage associated molecular patterns within xenogeneic biologic scaffolds and their effects on host remodeling. , 2012, Biomaterials.

[32]  Liu Yang,et al.  The expression of HMGB1 in nasal mucosa of allergic rhinitis patients and its significance. , 2010 .

[33]  L. Kalogjera,et al.  European Position Paper on Rhinosinusitis and Nasal Polyps , 2007 .